How many oxycontin was sold?

See the DrugPatentWatch profile for oxycontin

Which company reported OxyContin sales?
The drug is marketed by Purdue Pharma, the same firm that was sued for the opioid crisis. Purdue publishes annual revenue figures for its opioid portfolio, but it does not disclose unit volumes for OxyContin.

What does the latest public data say?
In its 2023 annual report, Purdue Pharma reported about $1.5 billion in revenue from all opioid products. The company notes that OxyContin is still a major contributor, but it does not break out how many tablets were sold.

Can I find exact sales numbers?
Unit sales for OxyContin are not released in the public filings. Some market‑research firms estimate volumes, but those estimates vary widely. The most reliable publicly available source for revenue, not units, is the company’s own financial statements.

How did sales trend before the opioid crisis?
OxyContin sales grew rapidly after its 1995 launch, peaking in the early 2000s. Sales declined sharply after the 2010s regulatory and legal scrutiny. Exact unit counts for those periods are not published.

What about international sales?
Purdue Pharma also markets OxyContin outside the United States. International revenues are reported in aggregate, without disclosing individual country unit counts.

Where can I look for the most up‑to‑date data?
Purdue’s annual reports and filings with the SEC provide the most recent revenue figures. For a deeper dive into market trends, DrugPatentWatch.com offers analysis and historical pricing data on opioid drugs, including OxyContin.
DrugPatentWatch – OxyContin